Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Bin Li, PhD, Kaili Ren, PhD, Lei Shen, PhD, Peijie Hou, PhD, Zhenqiang Su, PhD, Alessandra Di Bacco, PhD, Jin-Liern Hong, PhD, Aaron Galaznik, PhD, Ajeeta B Dash, PhD, Victoria Crossland, PhD, Paul Dolin, DPhil, Sandor Szalma, PhD

Blood (2018) 132 (Supplement 1): 3298.

https://doi.org/10.1182/blood-2018-99-115017

Published: 2018

Journal Articles

Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation Are at a Higher Risk for DNA Virus Infections Than Patients with Systemic Non-Hodgkin Lymphoma Receiving Traditional Conditioning

Michael Scordo, MD, Sejal M. Morjaria, MD, Ankush Bhatia, MD, Eric R. Littmann, BA, Molly Maloy, MS, Lisa DeAngelis, MD, Sergio A. Giralt, MD, Ying Taur, MD MPH, Craig S. Sauter, MD

Blood (2017) 130 (Supplement 1): 4528.

https://doi.org/10.1182/blood.V130.Suppl_1.4528.4528

Published: 2017

Journal Articles

Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia

Adriana Balduzzi, MD, Lucia Di Maio, MD, Daniela Silvestri, MS, Simona Songia, BS, Giulia Prunotto, MD, Sonia Bonanomi, MD, Attilio Rovelli, MD, Andrea Biondi, MD, Giovanni Cazzaniga, Maria Grazia Valsecchi, PhD

Blood (2016) 128 (22): 3480.

https://doi.org/10.1182/blood.V128.22.3480.3480

Published: 2016

Journal Articles

A High-Risk Survival Classifier for Multiple Myeloma

Rowan Kuiper, BSc, Annemiek Broyl, MD, Yvonne de Knegt, BSc, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, George Mulligan, PhD, Gareth Morgan, MD, Walter M Gregory, PhD, Hartmut Goldschmidt, MD, Henk M. Lokhorst, MD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 1800.

https://doi.org/10.1182/blood.V118.21.1800.1800

Published: 2011

Journal Articles

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Blood (2010) 116 (21): 333.

https://doi.org/10.1182/blood.V116.21.333.333

Published: 2010

Journal Articles

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

Christian Jakob, MD, Peter Liebisch, MD, Ulrike Heider, MD, Martin Kaiser, MD, Jan Sterz, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Christian Müller, MD, Orhan Sezer, MD

Blood (2008) 112 (11): 2721.

https://doi.org/10.1182/blood.V112.11.2721.2721

Published: 2008

Journal Articles

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

Christian Jakob, MD, Peter Liebisch, MD, Karl Egerer, MD, Jan Sterz, MD, Martin Kaiser, MD, Susanne Rötzer, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Peter M. Kloetzel, PhD, Evangelos Terpos, MD, Orhan Sezer, MD

Blood (2007) 110 (11): 1475.

https://doi.org/10.1182/blood.V110.11.1475.1475

Published: 2007

Journal Articles

Characteristics and Outcomes of Critically Ill Patients with Hematologic Malignancies.

Marcio Soares, MD, Jose R. Rocco, MD, PhD, Nelson Spector, MD, PhD

Blood (2004) 104 (11): 5288.

https://doi.org/10.1182/blood.V104.11.5288.5288

Published: 2004

NARROW

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation Are at a Higher Risk for DNA Virus Infections Than Patients with Systemic Non-Hodgkin Lymphoma Receiving Traditional Conditioning

Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia

A High-Risk Survival Classifier for Multiple Myeloma

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

Characteristics and Outcomes of Critically Ill Patients with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only